ClinicalTrials.Veeva

Find clinical trials for Acute Myeloid Leukemia (AML) in Boston, MA

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Acute Myeloid Leukemia
Leukemia
Myeloid Leukemia
Myelodysplastic Syndromes
Preleukemia
Syndrome
Cancer

Acute Myeloid Leukemia (AML) trials near Boston, MA, USA:

A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation

The purpose of this study is to determine the clinical benefit of ASP2215 therapy in participants with FMS-like tyrosine kinase (FLT3) mutated acute...

Active, not recruiting
Leukemia, Acute Myeloid (AML)
Drug: LoDAC (Low Dose Cytarabine)
Drug: MEC (Mitoxantrone, Etoposide, Cytarabine)

Phase 3

Astellas
Astellas

Boston, Massachusetts, United States and 125 other locations

A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML) (VIALE-T)

The main objective of this study is to evaluate the efficacy of venetoclax in combination with azacitidine to improve Overall Survival (OS) in Acute...

Active, not recruiting
Acute Myeloid Leukemia (AML)
Cancer
Other: Best Supportive Care (BSC)
Drug: Venetoclax

Phase 3

AbbVie
AbbVie

Boston, Massachusetts, United States and 164 other locations

CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

CLN-049-001 is a Phase 1, open-label, multicenter, first-in-human trial of CLN-049 in patients with Relapsed/Refractory Acute Myeloid...

Enrolling
Relapsed/Refractory Acute Myeloid Leukemia (AML)
Myelodysplastic Syndrome (MDS)
Drug: CLN-049

Phase 1

Cullinan Oncology Inc.

Boston, Massachusetts, United States and 6 other locations

A Study of JNJ-75276617 in Combination With Acute Myeloid Leukemia (AML) Directed Therapies

The purpose of this study is to determine the recommended Phase 2 dose (RP2D) candidate(s) of JNJ-75276617 in combination with AML directed ...

Enrolling
Leukemia, Myeloid, Acute
Drug: Azacitidine (AZA)
Drug: Cytarabine

Phase 1

Janssen
Janssen

Boston, Massachusetts, United States and 29 other locations

Revumenib in Combination With 7+3 + Midostaurin in AML

3) mutated Acute Myeloid Leukemia (AML).The names of the study drugs involved in this study are:Revumenib (SNDX-5...

Begins enrollment in 3 months
AML
AML, Adult
Drug: Daunorubicin
Drug: Cytarabine

Phase 1

Maximilian Stahl, MD

Boston, Massachusetts, United States and 1 other location

Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML)

A Phase 1/2 dose escalation study of BCL-2 Inhibitor ZN-d5 and the Wee1 Inhibitor ZN-c3 in Subjects with Acute Myeloid Leukemia...

Enrolling
Acute Myeloid Leukemia (AML)
Drug: ZN-c3
Drug: ZN-d5 ZN-c3

Phase 1, Phase 2

K-Group Alpha

Boston, Massachusetts, United States and 12 other locations

Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation

The purpose of this Phase I, multicenter, clinical trial is to evaluate the safety of AG-120 and AG-221 when given in combination with standard AML...

Active, not recruiting
Untreated AML
AML Arising From Antecedent Hematologic Disorder (AHD)
Drug: mitoxantrone
Drug: AG-221

Phase 1

Servier
Servier

Boston, Massachusetts, United States and 16 other locations

A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)

Anti-tumor Activity of LYT- 200 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML), or with Relaps...

Enrolling
AML, Adult Recurrent
MDS
Drug: Decitabine
Drug: LYT-200

Phase 1

PureTech Health

Boston, Massachusetts, United States and 10 other locations

A Study of Pevonedistat and Venetoclax Combined With Azacitidine to Treat Acute Myeloid Leukemia (AML) in Adults Unable to Receive Intensive Chemotherapy (PEVENAZA)

to venetoclax + azacitidine in adults recently diagnosed with AML who are unable to be treated with intensive chemotherapy.Participants will...

Active, not recruiting
Acute Myeloid Leukemia (AML)
Drug: Venetoclax
Drug: Pevonedistat

Phase 2

Takeda
Takeda

Boston, Massachusetts, United States and 56 other locations

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia (APTIVATE)

Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Tuspetinib (HM43239) in Patients with Relapsed or Refractory Acute...

Enrolling
Relapsed or Refractory Acute Myeloid Leukemia
Drug: Tuspetinib
Drug: Venetoclax Oral Tablet

Phase 1, Phase 2

Aptose Biosciences

Boston, Massachusetts, United States and 33 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2024 Veeva Systems